Persons and affiliations

Date

Description

Introduction: The optimal treatment of people with Parkinson's requires early diagnosis and the precise recording and monitoring of motor and non-motor symptoms as the basis for targeted therapy. Digital biomarkers are playing an increasingly important role here, as they enable automated, objective and often cost-effective recording of these symptoms. Objective: The symposium aims to present the role of digital biomarkers in diagnostics, symptom monitoring and prediction of disease progression in Parkinson's disease. The advantages over traditional methods will be discussed. Furthermore, an insight will be given into which methods can be implemented in home monitoring. Methods: The symposium will be organized by experts from the fields of phonetics, bioinformatics and neuropsychology, each of whom conduct interdisciplinary research in the field of Parkinson's disease. The speakers will provide a broad overview of how methods and results from the respective fields are used clinically in the treatment of Parkinson's disease. The methods presented range from motor assessments such as computer-assisted speech analysis, digital gait analysis, video-UPDRS and video-TUG to tablet-based methods for cognitive testing and home monitoring. In addition, the use of artificial intelligence (AI) to predict disease progression and optimize clinical study designs will be presented. Results: Computer-based speech analyses can already recognize characteristic speech abnormalities in the prodromal phase and enable differentiation from atypical Parkinson's syndromes. Together with sensor- and video-based assessments, they are suitable for more precise quantification of the severity of motor symptoms, the response to therapy and could enable monitoring in the home environment. Tablet-based cognitive tests, on the other hand, make life easier thanks to automation and the elimination of otherwise necessary supervision. AI-based patient stratification can significantly reduce the number of participants required in clinical trials. Conclusion: Digital biomarkers have the potential to revolutionize the diagnosis and monitoring of people with Parkinson's and thus contribute to optimal care for those affected. The symposium underlines the importance of these technologies and emphasizes the need to transfer these techniques more strongly into clinical practice.